Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells

Summary

This study evaluated direct effects of peroxisome proliferator-activated receptor γ (PPARγ) agonists, including thiazolidinediones (TZDs), on vascular cell apoptosis and related protein expression to test the hypothesis that these effects are dependent on i) the respective agent’s structure and ii) endothelial cells’ vascular origin. Exposure (48 h) of human umbilical vein endothelial cells (HUVECs, n=6) to up to 10μM troglitazone (TRO), rosiglitazone, pioglitazone, and to up to 50μM RWJ241947=MCC-555 (RWJ) inhibited (p<0.05) apoptosis by 8–25%, whereas 15-deoxy-Δ^12–14-prostaglandin J₂ (PGJ₂) triggered (50μM:+400%, p<0.05) endothelial cell death versus control (=100%). Moreover, RWJ (50μM) completely abrogated TNF-α (2000U/ml) and stearic acid (200μM) induced apoptosis in HUVECs. Similar results were obtained in human adult (saphenous) vein- and aortic endothelial cells, the latter showing no anti-apoptotic response to TRO. In HUVECs, TZDs’ anti-apoptotic effects inversely correlated (r=-0.95, p<0.01) with increased (p<0.05) expression of the apoptosis-inhibitor bcl-2, whereas PGJ₂-induced apoptosis was associated with upregulation of c-myc (+447%) and E2F-1 (+339%). Additionally, TZDs (by 25–39%) and PGJ₂ (-70%) reduced (p<0.05) expression of heat shock protein 60 (hsp60) showing no correlation with apoptosis (r=0.14, n.s.). Modulation of apoptosis by PPARγ agonists differs in endothelial cells dependent on their vascular origin and the agonists’ structure. Thiazolidinediones’ ability to reduce both, endothelial apoptosis and hsp60 expression could well add to beneficial vascular effects attributed to these oral antidiabetic drugs.

Keywords

Endothelium - PPARγ agonists - thiazolidinediones - apoptosis - heat shock protein 60

• References

• 1 Plutzky J, Viberti G, Haffner S. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: Mechanistic links and therapeutic targets. J Diabetes Compl 2002; 16: 401-15.
• 2 Plutzky J. Peroxisome proliferator-activated receptors in endothelial biology. Curr Opin Lipidol 2001; 12: 511-8.
• 3 Artwohl M, Fürnsinn C, Waldhäusl W. et al. Thiazolidinediones inhibit proliferation of micro- andmacrovascular cells by a PPARΥ-independent mechansims. Diabetologia 2005; 48: 586-94.
• 4 Theocharis S, Margeli A, Vielh P. et al. Peroxisome proliferator-activated receptor-gamma ligands as cellcyclemodulators. Cancer Treat Rev 2004; 30: 545-54.
• 5 Erl W, Weber C, Zernecke A. et al. Cyclopentenone prostaglandins induce endothelial cell apoptosis independent of the peroxisome proliferator-activated receptor- Υ. Eur J Immunol 2004; 34: 241-50.
• 6 Taba Y, Miyagi M, Miwa Y. et al. 15-Deoxy-△^12,14-prostaglandin J² and laminar fluid shear stress stabilize c-IAP1 in vascular endothelial cells. Am J Physiol Heart Circ Physiol 2003; 285: H38-H46.
• 7 Chen J, Li D, Zhang X. et al. Tumor necrosis factor- α-induced apoptosis of human coronary artery endothelial cells: Modulation by the peroxisome proliferator- activated receptor- Υligand pioglitazone. J Cardiovasc Pharmacol Ther 2004; 9: 35-41.
• 8 Artwohl M, Hölzenbein T, Wagner L. et al. Levamisole induced apoptosis in cultured vascular endothelial cells. Br J Pharmacol 2000; 131: 1577-83.
• 9 Artwohl M, Graier WF, Roden M. et al. Diabetic LDL triggers apoptosis in vascular endothelial cells. Diabetes 2003; 52: 1240-7.
• 10 Artwohl M, Roden M, Waldhäusl W. et al. Free fatty acids trigger apoptosis and inhibit cell cycle progression in human vascular endothelial cells. FASEB J 2004; 18: 146-8.
• 11 Chen J, Li D, Zhang X, Mehta JL. Tumor necrosis factor- α-induced apoptosis of human coronary artery endothelial cells: modulation by the peroxisome-proliferator- activated receptor- Υligand pioglitazone. J Cardiovasc Pharmacol Ther 2004; 9: 35-41.
• 12 Choy JC, Granville DJ, Hunt DWC. et al. Endothelial cell apoptosis: Biochemical characteristics and potential implications for atherosclerosis. JMol Cell Cardiol 2001; 33: 1673-90.
• 13 Nikitakis NG, Siavash H, Hebert C. et al. 15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells. Br J Cancer 2002; 87: 1396-403.
• 14 Fukuchi K, Date M, Azuma Y. et al. Apoptosis in human oral squamous cell carcinomas is induced by 15-deoxy-△^12,14-prostaglandin J₂ but not by troglitazone. J Dent Res 2003; 82: 802-6.
• 15 Tanaka H, Matsumura I, Ezoe S. et al. E2F1 and c-myc potentiate apoptosis through inhibition of NF- κB activity that facilitates MnSOD-mediated ROS elimination. Mol Cell 2002; 9: 1017-29.
• 16 Niculescu F, Niculescu T, Rus H. C5b-9 terminal complement complex assembly on apoptotic cells in human arterial wall with atherosclerosis. Exp Mol Pathol 2004; 76: 17-23.
• 17 Kleindienst R, Xu Q, Willeit J. et al. Demonstration of heat shock protein 60 expression and T-lymphocytes bearing α/βor Υ/δreceptor in human atherosclerotic lesions. Am J Pathol 1993; 142: 1927-37.
• 18 Hannan KM, Dilley RJ, de Dios ST. et al. Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta. Arterioscler Thromb Vasc Biol 2003; 23: 762-8.